List view / Grid view
3 September 2014 | By Novartis
Novartis announced that new analyses to be presented at the Joint ACTRIMS-ECTRIMS Meeting in Boston, USA from September 10-13, 2014...
20 August 2014 | By Novartis
Novartis has signed an exclusive worldwide licensing agreement with the Global Alliance for TB Drug Development for compounds to fight tuberculosis that have been discovered at the Novartis Institutes for Tropical Diseases...
11 August 2014 | By Novartis
New data revealing the reduction in cardiovascular deaths with Novartis' LCZ696 in patients with heart failure with reduced ejection fraction (HF-REF) will be presented at the world's largest cardiology congress...
4 August 2014 | By Novartis
Alcon announced that Simbrinza® eye drops suspension (brinzolamide 10mg/mL and brimonidine tartrate 2mg/mL) has been approved by the European Commission to decrease elevated intraocular pressure...
31 July 2014 | By Novartis
Novartis published clinical trial results in the New England Journal of Medicine showing that KAE609 (cipargamin), a novel and potent antimalarial drug candidate...
29 July 2014 | By Novartis
Novartis has announced the initial results of a large-scale vaccination campaign with Bexsero® to help protect against meningitis B within the Saguenay-Lac-Saint-Jean region of Québec, Canada...
28 July 2014 | By Novartis
Alcon, the global leader in eye care and a division of Novartis, announced that Simbrinza® eye drops suspension (brinzolamide 10mg/mL and brimonidine tartrate 2mg/mL) has been approved by the European Commission...
24 July 2014 | By Novartis
Sandoz announced that the US Food and Drug Administration has accepted its Biologics License Application for filgrastim...
15 July 2014 | By Novartis
Novartis announced a collaboration with Banner Alzheimer's Institute on a pioneering clinical study in Alzheimer's disease (AD) prevention...
9 July 2014 | By Novartis
Novartis has published a Corporate Responsibility (CR) Performance Report for 2013...
8 July 2014 | By Novartis
Novartis released new global guidelines for Investigator Initiated Trials...
30 June 2014 | By Novartis
Sandoz announces a long-term commitment to help prevent the deaths of millions of children worldwide by supplying a key antibiotic formulation...
18 June 2014 | By Novartis
For its first "Meet Novartis Management" investor day, Novartis gathered more than 20 of its top executives, drawn from the leadership of Pharmaceuticals...
17 June 2014 | By Novartis
Novartis announced the submission of a Biologic License Application to the US Food and Drug Administration for marketing approval for the use of Bexsero® (Multicomponent Meningococcal Group B Vaccine...
16 June 2014 | By Novartis
Novartis announced that the US Food and Drug Administration licensed its manufacturing facility in Holly Springs, N.C. for the production of cell-culture influenza vaccines...
